Itoh J, Nakagawa H, Sasaki H, Takahashi T, Katoh T
Gan To Kagaku Ryoho. 1983 Apr;10(4 Pt 2):1165-9.
Continuous hepatic arterial infusion chemotherapy (HAI) and chemoembolization by microcapsulated Mitomycin C (MMC-m. c) were performed in patients with unresectable hepatoma or metastatic tumors of the liver. MMC-m. c showed significant antitumor effect and improvement of survival rate in unresectable hepatoma and liver metastasis of the breast cancer. Especially in liver metastasis of the breast cancer, MMC-m. c gained 80% of partial response rate and 11 months in 50% survival time. HAI was effective in multiple liver metastasis of colon and stomach cancer, showing 40% of one-year survival rate. A combination chemotherapy of HAI and MMC-m. c was performed in two cases of liver metastasis of the colon cancer. Tumor response was 100% in partial response rate. One of them died at 8 months and the other is alive at 8 months now.
对无法切除的肝癌或肝转移瘤患者进行了肝动脉持续灌注化疗（HAI）以及微囊化丝裂霉素C（MMC-m.c）化疗栓塞。MMC-m.c对无法切除的肝癌及乳腺癌肝转移显示出显著的抗肿瘤作用并提高了生存率。尤其是在乳腺癌肝转移中，MMC-m.c的部分缓解率达80%，50%患者的生存时间为11个月。HAI对结肠癌和胃癌的多发性肝转移有效，一年生存率为40%。对2例结肠癌肝转移患者进行了HAI与MMC-m.c的联合化疗。部分缓解率的肿瘤反应为100%。其中1例在8个月时死亡，另1例目前已存活8个月。
